212 results on '"Schreck, Karisa C"'
Search Results
2. NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes
3. ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors
4. Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients
5. A brave new framework for glioma drug development
6. BRAF-Mutated Glioma
7. Correction to: Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients
8. Integrated molecular and clinical analysis of BRAF-mutant glioma in adults
9. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
10. Genomic Alterations in Molecularly Defined Oligodendrogliomas.
11. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
12. Subgroup and subtype-specific outcomes in adult medulloblastoma
13. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features
14. No drug holidays in BRAFV600E glioma patients: An argument for dose reduction of targeted therapies.
15. State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond
16. No drug holidays in BRAFV600E glioma patients: an argument for dose reduction of targeted therapies
17. Supplementary Table S3 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma
18. Supplementary Figure S3 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma
19. Supplementary Material 1 from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma
20. Data from Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma
21. MEK inhibition enhances the antitumor effect of radiation therapy in NF1-deficient glioblastoma
22. Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals
23. Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma
24. 1237 The Mutational Landscape of Molecularly Defined Oligodendrogliomas
25. No drug holidays in BRAFV600Eglioma patients: An argument for dose reduction of targeted therapies
26. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
27. Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma
28. Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
29. Frontal lobe mass in a 46‐year‐old woman
30. MEK inhibition enhances the antitumor effect of radiation therapy in NF1-deficient glioblastoma
31. Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid
32. Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System
33. Supplementary Tables 1-2 from Notch Signaling Promotes Growth and Invasion in Uveal Melanoma
34. Supplementary Figure Legends 1-5, Table Legends 1-2 from Notch Signaling Promotes Growth and Invasion in Uveal Melanoma
35. Supplementary Figure 1-2 from Notch Signaling Promotes Growth and Invasion in Uveal Melanoma
36. Supplementary Figure 3 from Notch Signaling Promotes Growth and Invasion in Uveal Melanoma
37. Supplementary Figure 4 from Notch Signaling Promotes Growth and Invasion in Uveal Melanoma
38. Supplementary Figure 5 from Notch Signaling Promotes Growth and Invasion in Uveal Melanoma
39. Supplementary Data from The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance
40. Data from Notch3 Activation Promotes Invasive Glioma Formation in a Tissue Site-Specific Manner
41. Supplementary Figure Legend from Notch3 Activation Promotes Invasive Glioma Formation in a Tissue Site-Specific Manner
42. Supplementary Figure 1 from Notch3 Activation Promotes Invasive Glioma Formation in a Tissue Site-Specific Manner
43. Druggable genomic landscapes of high-grade gliomas.
44. BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
45. Frontal lobe mass in a 46‐year‐old woman.
46. High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes
47. Molecular and clinical features of patients with glioblastoma treated with targeted therapy at Johns Hopkins Medicine
48. Notch Signaling Activation in Pediatric Low-Grade Astrocytoma
49. Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma
50. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.